D910B8Z
Brachytherapy Ear to None with Iridium 192 (Ir-192), Low Dose Rate (LDR) Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | D Radiation Therapy |
| Body System | 9 Ear, Nose, Mouth and Throat |
| Operation | 1 Brachytherapy |
| Body Part | 0 Ear |
| Approach | B Low Dose Rate (LDR) |
| Device | 8 Iridium 192 (Ir-192) |
| Qualifier | Z None |
Procedure Overview
Brachytherapy for ear, nose, mouth, and throat conditions involves placing a radioactive source directly into or next to a tumor, commonly in the oral cavity, tongue base, or nasopharynx. Because the source sits so close to the target tissue, it delivers a concentrated dose to the tumor while limiting exposure to surrounding healthy structures, which is valuable in a region crowded with nerves and tissue responsible for speech and swallowing.
The radioactive material may be temporary, removed after a set period, or permanently implanted depending on the isotope and clinical goal. This approach is often used alongside external beam radiation or surgery, particularly when a tumor recurs or when sparing normal tissue is a priority.
Anatomy & Axis Detail
Ear
The ear, encompassing the external auditory canal and structures of the outer and middle ear, is an uncommon but recognized site for radiation therapy, typically for rare skin or glandular malignancies arising in the canal or pinna. Brachytherapy allows radioactive sources to be placed directly within or adjacent to the ear canal, delivering a highly localized dose that spares surrounding facial and auditory structures compared to external approaches. The narrow, curved geometry of the canal and its proximity to the tympanic membrane and ossicles require specialized applicators suited to this confined anatomy. Because hearing function and facial nerve integrity are both at stake in this region, precise source placement and dose calculation are particularly important, and documentation should specify the ear as the treated structure distinct from surrounding skin or soft tissue.
Modality Qualifier: Low Dose Rate (LDR)
Low Dose Rate (LDR) denotes brachytherapy using a source of lower activity that remains implanted or applied over an extended period, from many hours to a few days, exploiting continuous low-level irradiation for tumor control. This differs from High Dose Rate (HDR), which compresses the same general goal into brief, higher-intensity sessions, and LDR is often chosen for permanent seed implants such as certain prostate treatments.
Isotope: Iridium 192 (Ir-192)
Iridium-192 is a gamma-emitting radioisotope used almost exclusively for high-dose-rate or pulsed-dose-rate brachytherapy, delivered via remote afterloader through catheters or applicators placed in or near the tumor. It allows a shaped, temporary dose to sites like the cervix, prostate, or breast cavity, then the source is withdrawn rather than left implanted, distinguishing it from permanent seed isotopes such as I-125 or Pd-103.
Coding & Documentation
Coders need documentation identifying the specific isotope or source used and confirming that the radioactive material was placed within or immediately adjacent to the target structure, not delivered from an external machine. The procedure note should specify whether the source is temporary or permanent, since this affects the qualifier assigned.